Reduced levels of amyloid β-peptide antibody in Alzheimer disease

Y. Du, R. Dodel, H. Hampel, K. Buerger, S. Lin, B. Eastwood, K. Bales, F. Gao, H. J. Moeller, W. Oertel, M. Farlow, S. Paul

Research output: Contribution to journalArticle

189 Scopus citations

Abstract

Objective: To investigate whether it was possible to detect the presence and different levels of naturally occurring anti-β-amyloid (Aβ) antibodies in the CSF of patients with AD and age-matched controls by employing a sensitive ELISA. Background: Immunization with preaggregated amyloid β-peptide (Aβ1-42) and administration of antibodies against Aβ into amyloid precursor protein APPV717F- transgenic mice (an animal model of AD) have recently been reported to dramatically reduce amyloid plaque deposition, neuritic dystrophy, and astrogliosis, most likely by enhancing Aβ clearance from brain. Methods: A sensitive ELISA was performed to detect levels of naturally occurring anti-Aβ antibodies in the CSF of patients with AD and age-matched controls. Additionally, an immunoprecipitation assay was performed to confirm that naturally occurring anti-Aβ antibodies also exist in the human blood. Result: Naturally occurring antibodies directed against Aβ were found in the CSF and plasma of patients with AD and healthy control subjects. Moreover, CSF anti-Aβ antibody titers are significantly lower in patients with AD compared with healthy control subjects. Conclusion: Naturally occurring antibodies directed against Aβ exist in human CSF and plasma. The CSF anti-Aβ antibody titers may be helpful in better understanding the effects of future immunologic therapies for AD.

Original languageEnglish (US)
Pages (from-to)801-805
Number of pages5
JournalNeurology
Volume57
Issue number5
DOIs
StatePublished - Sep 11 2001

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Du, Y., Dodel, R., Hampel, H., Buerger, K., Lin, S., Eastwood, B., Bales, K., Gao, F., Moeller, H. J., Oertel, W., Farlow, M., & Paul, S. (2001). Reduced levels of amyloid β-peptide antibody in Alzheimer disease. Neurology, 57(5), 801-805. https://doi.org/10.1212/WNL.57.5.801